---
title: "Repatha (evolocumab) in cardiovascular event risk reduction: Dosing and administration questions"
description: "Dosing and administration questions on Repatha (evolocumab) in cardiovascular event risk reduction, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing. Questions: What is the Repatha dose for cardiovascular risk reduction? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Repatha (evolocumab) in cardiovascular event risk reduction: Dosing and administration questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)

Dosing and administration questions that apply to every indication of Repatha are on [Repatha (evolocumab), all indications: Dosing and administration](https://www.evicenter.com/medical-information/repatha/dosing-and-administration).

## Dosing

<a id="repatha-dose"></a>

### What is the Repatha dose for cardiovascular risk reduction?

> “In adults at increased risk for CV events or with hypercholesterolemia: 
> • 
> The recommended dosage of REPATHA is either 140 mg every 2 weeks OR 420 mg 
> once monthly administered subcutaneously [see Dosage and Administration (2.3)]. 
> • 
> If switching dosage regimens, administer the first dose of the new regimen on the next 
> scheduled date of the prior regimen.”

Source: [REPATHA: Prescribing information, page 2, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=2)

Note: Quoted from the Prescribing Information revised 10/2026.

## Related pages
- [Medical information: Repatha (evolocumab): Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)
- [Indication](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/safety)
- [Guidelines](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/guidelines)
